Wyeth rated best in WSJ patent scorecard

The Wall Street Journal's "Patent Scorecard" ranks Wyeth first among 35 global pharmaceutical companies evaluated for patent-based intellectual property, as measured by indicators including patents granted; quality of patents; Science Strength, or the degree to which a company's patent portfolio is linked to core science; Research Intensity, a comparative measure of the level of basic research; and Innovation Cycle Time, or the speed at which research results in patent assets.

Announcing the news, Wyeth said its score on the Science Strength component was 9,801.08, compared to 7,334 for the nearest competitor, and the company outperformed the industry average by more than two fold on the Research Intensity measure. The Scorecard also compares stock performance for the leading company versus the industry.

"Wyeth has made considerable effort to increase its scientific strength via ongoing investment in our people, technology and resources, with an ultimate goal of delivering to patients and doctors two new medicines each year," says Robert Ruffolo, president of Wyeth R&D.